Email
azhang@xppharmaconsulting.com
11 Coventry Ln,
Stoneham, MA 02180
Home
About Us
About XP Pharma Consulting
Meet Our CEO
Services
Pre-IND to IND
Early Phase
Late Phase
NDA/BLA Filing
Clinical Pharmacology Studies
Clinical Pharmacology Strategy and Writing
Noncompartmental PK Analysis (NCA)
PK/PD Modeling & Simulation
Case studies
Dose Justification with PK Exposure-Response Analysis
Assessment of Drug-Drug Interaction Potential
Determine First-in-Human Study Doses with M&S
Risk Assessment for QT Prolongation Potential
Record Of Success
Contact Us
Clinical Pharmacology Strategy and Writing
Clinical Pharmacology Strategy and Writing
Gap analyses and mitigation strategy
Due diligence (asset evaluation)
Clinical pharmacology plans
Clinical study designs
Clinical Study protocols (in full or in part)
Clinical Study reports and/or standalone PK report
Regulation document preparations (PK/PD)
Clinical development plans (in full or in part) and reviews
Responses to regulatory questions (in full or in part) and reviews
Comparator PK/PD data analyses
Regulatory meeting representations
Dose rationale and justification
PK/PD design in the study protocols
Inclusion/exclusion criteria
Assessment of Drug-drug interaction (DDI) potential
Drug-drug interaction (DDI) waiver justifications
Assessment of risk for QT prolongation potential
Thorough QT (TQT) waiver justification
Pediatric drug development and dose determination
Contact us today to discuss how we can help you
© Copyright 2024. All Right Reserved.